Background: Propofol binding to GABA A R sites of uncertain location potentiates receptor function and produces anesthesia in vivo. Results: A photoreactive propofol analog identifies propofol-binding sites in ␣1␤3 GABA A Rs. Conclusion: Propofol binds to each class of intersubunit sites in the GABA A R transmembrane domain. Significance: This study demonstrates that propofol binds to the same sites in a GABA A R as etomidate and barbiturates.
helix (␤M2-15Ј) and four of the M3 helix (␤M3-4Ј, ␤3Met-286), numbered relative to the conserved Arg and Asp near the N terminus of each subunit's M2 and M3 helices, respectively (7, 8) . In addition, positions in ␤M4 (9) and in the ␣ subunit cytoplasmic domain (10) have been identified as propofol sensitivity determinants. These propofol sensitivity determinants can be located in models of heteromeric GABA A Rs constructed by homology from the recently solved structure of a homomeric ␤3 GABA A R (11) or the structures of other pentameric ligandgated ion channels, including the Torpedo nicotinic acetylcholine receptor (nAChR) (12) , the prokaryotic proton-gated channel GLIC (13) , the amine-gated channel ELIC (14) , and the invertebrate glutamate-gated channel GluCl (15) . In these models, ␤M2-15Ј and ␤M3-4Ј, positions that are also sensitivity determinants for the intravenous anesthetic etomidate, are present in a pocket at the interface between the ␤ and ␣ subunits that contains the transmitter-binding sites in the extracellular domain (referred to as the ␤ ϩ -␣ Ϫ interface) (16, 17) , although the other sensitivity determinants are not within that intersubunit pocket. That etomidate binds to this intersubunit site was established by the etomidate-inhibitable photoincorporation of reactive etomidate analogs into ␤M3-4Ј and ␣1Met-236 in ␣M1 in a heterogeneous population of GABA A Rs purified from bovine brain (18) and in purified human ␣1␤3 GABA A R (16) .
Recently, photoaffinity labeling studies with R-[ 3 H]mTFD-MPAB, a photoreactive barbiturate, identified a second class of general anesthetic-binding sites in human ␣1␤3␥2 GABA A Rs at the ␤ Ϫ -␣ ϩ and ␤ Ϫ -␥ ϩ subunit interfaces (19) . Although etomidate bound selectively to the ␤ ϩ interface sites and certain barbiturates bound selectively at the ␤ Ϫ interface sites, propofol inhibited photolabeling at both classes of sites, but only at concentrations (IC 50 ϳ40 M) that were ϳ10-fold higher than the concentrations necessary to potentiate GABA responses. This discrepancy suggests that propofol may bind with higher affinity to other, as yet unidentified, sites in the GABA A R. A reactive propofol analog (o-propofol diazirine (o-PD)) was recently shown to photoincorporate in expressed ␣1␤3 GABA A R into ␤3His-267 (␤M2-17Ј), an amino acid in the ␤ subunit M2 helix in proximity to the R-mTFD-MPAB site, but projecting into the lumen of the ion channel near the interface between the extracellular and transmembrane domains (20) .
In this report, we identify propofol-binding sites in a purified human ␣1␤3 GABA A R using 2-isopropyl-5-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenol (AziPm), a photoreactive propofol analog that potentiates GABA responses and acts as a general anesthetic ( Fig. 1) (21) . Propofol and AziPm are nAChR inhibitors, and photoaffinity labeling of the Torpedo nAChR established propofol-inhibitable photoincorporation of [ 3 H]AziPm into two sites in the TMD as follows: an intrasubunit site in the ␦ subunit helix bundle, and a site in the ion channel (22) . Propofol and AziPm are also inhibitors of GLIC, and in GLIC crystals propofol binds in the TMD in the intrasubunit pocket formed by the four transmembrane helices (23) . In purified GLIC in detergent solution, propofol inhibited [ 3 H]AziPm photolabeling of amino acids in that binding pocket (24) . Based upon the identification of the GABA A R amino acids photolabeled by [ 
EXPERIMENTAL PROCEDURES
Materials-Nonradioactive AziPm was synthesized as described (21) (26) , which was also resynthesized at 19 Ci/mmol by catalytic reduction of m-bromoazietomidate with tritium gas. o-PD was synthesized from 2-isopropyl-6-trifluoroacetylphenol as described (20) with the purity Ͼ96% as judged by 1 H and 19 F NMR. As reported (20) , the UV spectrum was characterized by an absorption maximum at 280 nm (extinction coefficient, ⑀ 280 ϭ 2417 Ϯ 24 M Ϫ1 cm Ϫ1 ) and an unresolved long wavelength shoulder (⑀ 350 ϭ 66 Ϯ 1 M Ϫ1 cm
Ϫ1
), and when stored in ethanol at Ϫ20°C, o-PD was stable for more than 1 month. n-Dodecyl-␤-D-maltopyranoside, sodium cholate, and CHAPS were from Anatrace-Affymetrix (Anagrade quality). (R)-Etomidate was from Organon Laboratories. Soybean asolectin, FLAG peptide (DYKDDDDK), ␥-aminobutyric acid (GABA), propofol, 3-bromo-3-methyl-2-(2-nitrophenylthio)-3H-indole (BNPS-skatole), and cyanogen bromide (CNBr) were from Sigma. o-Phthalaldehyde (OPA) was from Alfa Aesar. Lysobacter enzymogenes lysine-C endopeptidase (EndoLys-C) was from Roche Applied Science, and Staphylococcus aureus glutamic-C endopeptidase (EndoGlu-C) was from Princeton Separations.
Purification of Expressed ␣1␤3 GABA A Rs-␣1␤3 GABA A Rs containing the FLAG epitope at the N terminus of the ␣1 subunit were purified from a tetracycline-inducible, stably transfected HEK293S cell line (27) . Briefly, membrane fractions containing 6 -10 nmol of [ 3 H]muscimol-binding sites, collected from cells growing on 40 -60 tissue culture dishes (15 cm), were resuspended at 1 mg of protein/ml and solubilized overnight in 300 ml of a purification buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM CaCl 2 , 5 mM KCl, 5 mM MgCl 2 , 4 mM EDTA, 20% glycerol, pepstatin, chymostatin, and leupeptin (10 g/ml each), 2 g/ml aprotinin, and 1 mM phenylmethanesulfonyl fluoride) supplemented with 2.5 mM n-dodecyl-␤-D-maltopyranoside. Solubilized FLAG-␣1␤3 GABA A Rs were purified by elution from an anti-FLAG M2 affinity resin in elution buffer (purification buffer supplemented with 11.5 mM cholate, 0.86 mM asolectin, and 1.5 mM FLAG peptide). For competition photolabeling studies, GABA A R was also purified by solubilization for 2.5 h in purification buffer supplemented with 30 mM n-dodecyl-␤-D-maltopyranoside followed by elution from the anti-FLAG affinity resin after washing in purification buffer supplemented with 5 mM CHAPS and 0.2 mM asolectin, as described for the ␣1␤3␥2 GABA A R (19) . For both protocols, typical purification yields were ϳ1. After photolabeling on a preparative scale, GABA A R subunits were recovered from the excised gel bands as described (16) and resuspended in 200 l of digestion buffer (15 mM Tris, 500 M EDTA, and 0.1% SDS (pH 8.5)). Aliquots (ϳ90 l) from gel bands enriched in ␣1 or ␤3 subunits were digested at room temperature with 0.5 units of EndoLys-C for 14 days or 2.5 g of EndoGlu-C for 2-4 days, following which the digests were fractionated by HPLC or directly subjected to protein microsequence analysis. For chemical cleavage at the C terminus of methionines, samples immobilized on PVDF sequencing filters were treated with cyanogen bromide as described (28, 29) . For chemical cleavage at the C terminus of tryptophans, samples on PVDF filters were treated with BNPS-skatole as described (30) , except that after precipitation of excess BNPS-skatole, the digestion solution was loaded onto a second PVDF filter, and material on the two filters was sequenced simultaneously (16) . ␣1␤3 GABA A R amino acids photolabeled by R-[
3 H]mTFD-MPAB were identified as described for the ␣1␤3␥2 GABA A R (19) .
Quantification of Anesthetic Inhibition of GABA A R Photolabeling-The concentration dependence of inhibition of 3 H incorporation into GABA A R subunits was fit by nonlinear least squares using SigmaPlot to a single site model, Equation 1,
where f(x) is the 3 H counts/min (cpm) incorporated into a subunit at the inhibitor total concentration x; f 0 is the subunit 3 H in the absence of inhibitor; IC 50 is the total inhibitor concentration reducing photolabeling by 50%, and f ns is the nonspecific subunit photolabeling. IC 50 3 H]AziPm, inhibition of photolabeling was quantified only for the ␤ subunit bands, as pharmacologically specific photolabeling was too small a component of ␣ subunit photolabeling. For GABA A R purified in 0.2 mM asolectin, 5 mM CHAPS, photolabeling in the presence of nonradioactive AziPm at concentrations Ͼ30 M resulted in GABA A R aggregation, as evidenced by decreased stain intensity of GABA A R subunit gel bands after SDS-PAGE. IC 50 values for AziPm were determined from data at concentrations Յ30 M.
Reversed-phase HPLC and Sequence Analysis-Subunit fragments generated by enzymatic digestion were fractionated by reversed phase HPLC (rpHPLC) on an Agilent 1100 binary HPLC system, using a Brownlee C4-Aquapore column (100 ϫ 2.1 mm, 7 particle size) at 40°C. Solvent A was 0.08% trifluoroacetic acid in water, and solvent B was 0.05% trifluoroacetic acid in 60% acetonitrile and 40% 2-propanol. A nonlinear elution gradient increasing from 5 to 100% solvent B in 80 min was used at a flow rate of 200 l/min, with 0.5-ml fractions collected. 3 H distribution was determined by counting aliquots (10%) of each fraction, and peptide elution was monitored by absorbance at 215 nm. The rpHPLC fractions containing peaks of 3 H were pooled and drop-loaded at 45°C onto Micro TFA glass fiber filters (Applied Biosystems). Digests of intact GABA A R subunits and selected rpHPLC fractions were loaded directly onto PVDF filters using Prosorb (Applied Biosystems) sample preparation cartridges. All filters were treated after loading with Biobrene (Applied Biosystems) before sequencing.
Samples were sequenced using a Procise 492 protein sequencer (Applied Biosystems) programmed to use 2 ⁄ 3 of the material from each cycle of Edman degradation for PTH-derivative quantification and 1 ⁄ 3 to measure the 3 H release by scintillation counting. For some samples, sequencing was interrupted at designated cycles, and the sample filter was treated with OPA to chemically isolate for further sequencing only those fragments containing a proline in the designated cycle. OPA reacts with primary amines, but not secondary amines, and treatment with OPA blocks further sequencing of any fragment not containing a proline at that cycle (31, 32) . The amount of PTH-derivative released (in picomoles) for a given residue was quantified using their peak height in the chromatogram, background-corrected, compared with a standard peak, and fit by nonlinear least squares to Equation 2,
where I x is the mass of the peptide residue in cycle x (in picomoles); I 0 is the initial amount of peptide (in picomoles), and R is the average repetitive yield. Amino acid derivatives whose amounts could not be accurately estimated (His, Trp, Ser, Arg, and Cys) were omitted from the fit. The efficiency of photolabeling (in cpm/pmol) for a given amino acid residue was calculated by Equation 3 ,
where cpm x is the 3 H released in cycle x. Molecular Modeling-The Discovery studio 2.5.5 molecular modeling package (Accelrys, Inc.) was used as described (19) to dock propofol, AziPm, and o-PD in potential anesthetic binding pockets in two homology models of a human ␣1␤3 GABA A R with a ␤3-␣1-␤3-␣1-␤3 subunit order as follows: (i) a model described previously (16) derived from the crystal structure of GLIC (Protein Data Bank code 3P50); and (ii) a model based upon the recently published structure of a human homopentameric ␤3 GABA A R ((Protein Data Bank code 4COF (11) ). This new model was created by replacing the ␤3 sequences of the subunits designated A and C with the human ␣1 sequence, an alignment requiring two single residue insertions in the structure at ␣1Thr-172 and ␣1Gly-185 and the removal of the cytoplasmic loop between M3 and M4 (␣1Arg-313 to ␣1Lys-383) and N-and C-terminal truncations. This model was placed within a membrane force field and partially minimized to eliminate high energy interactions induced by the ␣1 sequence replacements (two cycles of minimization, final system energy ϭ Ϫ211,878 kcal/mol). Although propofol, AziPm, or o-PD docked readily at the intersubunit anesthetic-binding site at the ␣ ϩ -␤ Ϫ interface, we were unable to dock to the ␤ ϩ -␣ Ϫ or ␤ ϩ -␤ Ϫ interfaces without modifying the side chain orientations of ␤3Asn-265 (␤M2-15Ј) and/or ␣1Met-236 (in ␣M1). After these side chains were rotated out of the pockets, propofol was placed into the ␤3-␣1 or ␤3-␤3 pocket, and the system was minimized for two cycles, followed by 10 additional cycles of minimization after removal of propofol. The CHARMm-based molecular dynamics simulated-annealing program CDOCKER was used to dock propofol, AziPm, and o-PD within the pockets in the transmembrane domain at the
Ϫ subunit interfaces and in the intersubunit pockets accessible from the ion channel in proximity to ␤3His-267 (␤3 GABA A R-based model only; no pocket in the GLIC-based model). We also docked the anesthetics at the top and bottom of the ion channel and in the intrasubunit pockets. Although no intrasubunit pockets were present in the ␤3 GABA A R-based model, in the GLIC-based model ␤3His-267 contributed to the ␤3 subunit pocket. For the intersubunit sites, randomly oriented and randomly distributed molecules of propofol (9 -30), AziPm (6 -30), and o-PD (6) were seeded within binding site spheres (12 Å radii) centered on the proposed anesthetic-binding sites defined between M2-15Ј, the conserved proline in M1 (␣1Pro-233/␤3Pro-228), and the conserved aromatic residue in M3 (␣1Tyr-294/␤3Phe-289). For each binding site, CDOCKER was set up to first generate 10 -40 random conformations for each replica using high temperature molecular dynamics, and 10 -40 random orientations of each molecule were generated within the binding site spheres. The lowest 25-100 energyminimized docking solutions, generated using simulated annealing and full potential minimization, were collected and ranked according to CDOCKER interaction energies. In the ␤3 GABA A R model, all three anesthetics were predicted to bind stably at the following: 1) each intersubunit anesthetic-binding site; 2) at each ␤3His-267-associated pocket near the ion channel; and 3) at the bottom of the ion channel at the levels of M2-2Ј-M2-6Ј. Less favorable binding was predicted in the ion channel at the level of M2-13Ј. Communication between the ␤-␤ intersubunit anesthetic sites and the ␤3His-267-associated pocket at the ␤-␤ interface near the ion channel was blocked by ␤3Pro-228 from M1 on the ␤ Ϫ side and from ␤3Thr-262 (M2-12Ј) and ␤3-Thr-266 (M2-16Ј) from M2 on the ␤ ϩ side in the crystal structure. In the GLIC-based model using CDOCKER interaction energies, AziPm and propofol were each predicted to bind with highest affinity at the ␤ ϩ -␣ Ϫ and ␤ ϩ -␤ Ϫ interface, and with lower affinity at the ␣ H]AziPm, 300 M propofol inhibited photolabeling in ␣1 and ␤3 subunits by ϳ30 and 50%, respectively, and 100 M etomidate or R-mTFD-MPAB, alone or in combination, inhibited ␤ subunit photolabeling by 60% (Fig. 3) . We also found that nonradioactive AziPm at 30 M inhibited subunit photolabeling to the same extent as propofol (data not shown). Although at the level of intact GABA A R subunits ϳ90% of [ 3 
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H]azietomidate and R-[
3 H]mTFD-MPAB photolabeling was pharmacologically specific (Fig. 2) 3 H]AziPm (10 Ci/mmol), the 5,500 cpm of propofol-inhibitable incorporation in the ␤3 subunit gel bands (ϳ1,000 cpm/pmol ␤3 subunit) indicated photolabeling of ϳ10% of ␤3 subunits, and the ϳ1,000 3 H cpm of propofolinhibitable ␣1 subunit incorporation (280 cpm/pmol) indicated photolabeling of 3% of ␣1 subunits. We also determined the concentration dependence of the inhibition of [ 3 H]AziPm photolabeling by these anesthetics (Fig. 3C and 
H]mTFD-MPAB in the presence of propofol (Ⅺ), AziPm (E), o-PD (F), etomidate (ࡗ), and nonradioactive R-mTFD-MPAB (OE). For each condition, plotted values are the average inhibition from two independent photolabeling experiments.
The concentration dependences of inhibition were fit independently for each experiment as described under "Experimental Procedures," and the means of the IC 50 values (Ϯ range), the total anesthetic concentration reducing specific photolabeling by 50%, are tabulated in Table 2 .
Localization of GABA A R Structural Domains Containing Amino Acids Photolabeled by [
3 H]AziPm-To provide an initial characterization of the GABA A R subunit regions containing photolabeled amino acids, GABA A Rs were photolabeled on a preparative scale with [ 3 H]AziPm in the absence and presence of propofol, and rpHPLC was used to fractionate EndoLys-C and EndoGlu-C digests of material eluted from the gel bands enriched in ␤3 subunits (Fig. 4) and ␣1 subunits (data not shown). For both digests, all 3 H was eluted in two broad peaks in a region of the gradient (50 -70% solvent B) reported previously to contain fragments beginning near the N terminus of the M1 and M3 helices (16) , and no 3 H was recovered in the hydrophilic fractions containing fragments from extracellular domains of GABA A R subunits.
Aliquots of the EndoLys-C digests of labeled ␣1 and ␤3 subunits were sequenced to identify the cycles of Edman degradation with peaks of 3 H release indicative of the presence of a photolabeled amino acid (Fig. 5) . In the ␣1 subunit digest, there were peaks of 3 H release in cycles 17 and 19. In the ␤3 subunit digest, there was a peak of 3 H release in cycle 12. Because the digests contained all subunit fragments, peaks of 3 H release could not be directly associated with specific subunit fragments. However, based upon the rpHPLC fractionation of the subunit digests, [ 3 H]AziPm was likely to be incorporated into one or more of the subunit transmembrane helices. For each subunit, digestion with EndoLys-C produced fragments beginning before the M1, M3, and M4 helices (Fig. 5) . Therefore, for the ␣1 subunit digest, the peaks of 3 H release in cycles 17 and 19 would be consistent with photolabeling in ␣M1 of ␣1Ile-239 in the fragments beginning at ␣1Arg-223 or ␣1Ile-221, respectively. For the ␤3 subunit digest, the peak of 3 H release in cycle 12 was consistent with photolabeling in ␤3M1 of ␤3Met-227, the amino acid photolabeled by R-[ (Fig. 6) . First, an EndoLys-C digest of the ␣1 subunit was sequenced with OPA treatment in cycle 11 (at ␣1Pro-233) to prevent further sequencing of other fragments not containing a proline at IC 50 values, the total anesthetic concentrations resulting in 50% inhibition of photolabeling of ␣1␤3 GABA A R purified in 0.2 mM asolectin, 5 mM CHAPS, were determined as described under "Experimental Procedures" (mean Ϯ range, two independent experiments); EC 50 value for anesthesia, tadpole loss of righting reflex. (16); the ϳ56-kDa band contained primarily the ␣1 subunit, and the ϳ59 and ϳ61-kDa bands contained differentially glycosylated ␤3 subunits. Subunit cross-contamination was ϳ10%. B and C, 3 H incorporation into GABA A R subunits, determined by liquid scintillation counting of the subunit bands excised from the gel. B, [ Table 2 .
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that cycle (18, 31) . After OPA treatment, the fragment beginning at ␣1Ile-223 was the primary sequence, and the peak of 3 H release at cycle 17 was consistent with photolabeling of ␣1Ile-239, with propofol inhibiting photolabeling by ϳ60% (Fig. 6A) 3 H]AziPm in the absence (F, Ⅺ) or presence (E) of 100 M propofol were loaded directly onto PVDF filters and sequenced, with OPA treatment in cycle 11 to chemically isolate during further sequencing the ␣1M1 fragment with ␣1Pro-233 in that cycle. After OPA treatment, the primary sequence began at ␣1Thr-223 (I 0 ϭ 10 pmol, both conditions), with a secondary sequence beginning at ␣Ile-392 (I 0 ϭ 3 pmol). The peak of 3 H release in cycle 17 was consistent with photolabeling of ␣1Ile-239 in the primary sequence (ϪPPF/ϩPPF, 244/114 cpm/ pmol), and the minor peak of 3 H release in cycle 14 indicated photolabeling of ␣1Met-236 (ϪPPF/ϩPPF, 27/7 cpm/pmol). B, EndoGlu-C digests of ␣1 subunits from GABA A Rs photolabeled by 8 M [
3 H]AziPm in the absence (F, Ⅺ) or presence (E) of 300 M propofol were fractionated by rpHPLC, and fractions containing the peak of 3 H were loaded onto glass fiber filters, treated with CNBr (see "Experimental Procedures"), and sequenced. The primary sequence began at ␣Thr-237 within ␣1M1 (Ⅺ, I 0 ϭ 40 pmol, both conditions), with secondary sequences beginning at ␣Asp-287 at the N terminus of ␣M3 (I 0 ϭ 20 pmol) and a contaminating ␤3 subunit fragment beginning at ␤3Gly-287 in ␤M3 (I 0 ϭ 10 pmol). The peak of 3 H release in cycle 3 was consistent with photolabeling of ␣Ile-239.
etomidate (16) . As the fragment beginning before ␣M4 at ␣1Ile-392 was present as a secondary sequence after OPA treatment in cycle 11 (due to the presence ␣1Pro-401), we used an alternative sequencing strategy to confirm photolabeling of ␣1Ile-239 that depended upon CNBr cleavage at ␣1Met-236. When the fragment beginning at ␣1Thr-237 was sequenced for 25 cycles, there was a peak of 3 H release only in cycle 3, consistent with photolabeling of ␣1Ile-239 (Fig. 6B) .
[ 3 H]AziPm Photolabels ␤3Met-227 in ␤M1 and ␤3Met-286 in ␤M3-EndoLys-C digests of photolabeled ␤ subunits were fractionated by rpHPLC, and the two peaks of 3 H (Fig. 4A) were pooled separately for sequence analysis (Figs. 7 and 8) . The more hydrophobic peak (Fig. 7) contained as the primary sequence the fragment beginning at ␤3Arg-216 near the N terminus of ␤M1 (70 pmol) and a secondary sequence beginning at ␤3Ala-280, the N terminus of ␤M3 (18 pmol). The major peak of 3 H release in cycle 12 would correspond to photolabeling in the primary sequence of ␤3Met-227 within ␤M1, with propofol inhibiting photolabeling by ϳ85%. Photolabeling of ␤3Met-227 was confirmed by the peak of 3 H release seen in cycle 37 when a fragment beginning at ␤3His-191 was sequenced with OPA treatment in cycle 16 (␤3Pro-206) (Fig. 7, inset ). The peak of 3 H eluting first in the rpHPLC fractionation contained the fragment beginning at ␤3Ala-280 (20 pmol) and fragments beginning before ␤M4 at ␤3-414 (26 pmol) and ␤3-412 (19 pmol) (Fig. 8 ). The peak of 3 H release in cycle 7 indicated propofolinhibitable photolabeling of ␤3Met-286 within ␤M3, because that release could not result from photolabeling of ␤3Val-420 before ␤M4 in the absence of a peak of 3 H release in cycle 9 from that position in the ␤3Ile-412 fragment. 
H]AziPm Photolabeling in Other Transmembrane Helices-
Photolabeling within ␤M2, if it occurred, was at Ͻ15% the efficiency of ␤3Met-227, based upon the levels of 3 H released during sequencing of a sample containing the fragment beginning at ␤3Ile-242 (11 pmol), produced by BNPS-skatole cleavage at ␤3Trp-241. Photolabeling within ␣M2, if it occurred, was at Ͻ10% the efficiency of ␣1Ile-239, based upon sequence analysis of the fragment beginning before ␣M2 at ␣1Ser-251 (6 pmol) produced by subunit digestion with EndoGlu-C and then chemical isolation of that fragment during sequence analysis by treatment with OPA at cycle 3. Photoincorporation within ␣M3 was characterized when the fragment beginning at ␣1Asp-287 was sequenced along with the fragment beginning at ␣1Thr-237 (Fig. 6B) . Because no peak of 3 H release was detected other than the peak in cycle 3 expected for the photolabeling of ␣1Ile-239, any photolabeling in ␣M3 was at Ͻ15% the efficiency of ␣1Ile-239.
DISCUSSION
In this study, we characterize the interactions of propofol with the ␣1␤3 GABA A R by directly identifying the GABA A R amino acids photolabeled by of Edman degradation for samples enriched in ␤M1-␤M2 (Fig. 7) or ␤M3/ ␤M4 (Fig. 8 ) that was not seen for ␣1 subunit samples. The source is unknown for this incorporation that is unstable under the acid and/or base treatments necessary for Edman degradation, but there was no evidence of unstable 3 H incorporation when enzymatic digests of ␤ subunits were fractionated by rpHPLC in 0.1% trifluoroacetic acid (Fig. 4) . 3 H (F, E) and PTHderivatives (Ⅺ, ‚) released during sequencing of fragments isolated by rpHPLC (Fig. 4A, fractions 27-29) from EndoLys-C digests of ␤3. The primary sequence began at ␤3Arg-216 near the N terminus of ␤M1 (Ⅺ, I 0 ϭ 70 pmol, both conditions), with a secondary sequence beginning at ␤3Ala-280 before ␤M3 (‚, I 0 ϭ 18 pmol, both conditions). The peak of 3 H release in cycle 12 indicated photolabeling of ␤3Met-227 in ␤M1 (ϪPPF/ϩPPF, 18/3 cpm/pmol). Inset, direct sequencing of an EndoGlu-C digest of photolabeled ␤3 59 kDa , with OPA treatment in cycle 16 to chemically isolate during further sequencing the fragment beginning at ␤3His-191 (25 pmol) that contains ␤3Pro-206 in cycle 16 and extends through ␤M1. The peak of 3 H release in cycle 37 confirmed photolabeling of ␤3Met-227 (18 cpm/pmol, ϪPPF). 3 H (F, E) and PTH-derivatives (Ⅺ) released during sequencing of fragments isolated by rpHPLC (Fig. 4A, fractions 25-26 ) from EndoLys-C digests of ␤3 subunits. The major fragments present began at ␤3Ala-280 before ␤M3 (Ⅺ, I 0 ϭ 21 pmol, both conditions) and fragments beginning before ␤M4 at ␤3Ile-412 (20 pmol, both conditions) and ␤3Ile-414 (26 pmol, both conditions). The peak of 3 H release in cycle 7 indicated photolabeling of ␤3Met-286 in ␤M3 (ϪPPF/ϩPPF: 3/0.4 cpm/pmol). The minor peak of 3 H release in cycle 7 when HPLC fractions 27-29 were sequenced (Fig. 7 ) was also consistent with propofol-inhibitable photolabeling of ␤3Met-286.
interface of a pocket accessible from the ion channel and in contact with ␤3His-267, the residue photolabeled by o-PD (20) . Also included in the figure is an alignment of ␣1 and ␤3 subunit sequences in the M1-M3 transmembrane domain with the photolabeled amino acids highlighted.
Expanded views of the intersubunit-binding sites are shown in Fig. 10 with AziPm docked in the lowest energy orientation predicted by computational docking and the amino acids identified in ␣M1, ␤M1, and ␤M3 that are photolabeled by [ 3 H]AziPm and in ␤M2 by o-PD (␤3His-267 (␤M2-17Ј) (20) ). Also highlighted are the amino acids photolabeled by photoreactive etomidates and R-mTFD-MPAB and those identified by mutational analyses as propofol sensitivity determinants (␤3M2-15Ј (␤3Asn-265), ␤3M3-4Ј (␤3Met-286), and ␤3Tyr-442 in ␤M4 (7-9)). ␤3Asn-265, the in vitro (7) and in vivo (3) sensitivity determinant, as well as the photolabeled/sensitivity determinant ␤3Met-286 and photolabeled ␣1Met-236 all contribute to the pocket at the ␤ ϩ -␣ Ϫ interface between the ␤M2/␤M3 and ␣M2/␣M1 helices (Fig. 10, A and B) . Photolabeled ␣Ile-239 is located at the same interface, approximately one helical turn below ␣1Met-236 and more lipidexposed. Analyses of the reactivities of Cys mutant GABA A Rs identify state-dependent changes in the structure of the ␤ ϩ -␣ Ϫ subunit interface at the level of ␣1Met-236 and ␤3Met-286 (36), although the studies do not determine whether those changes involve rotations of helices that would bring ␣1Ile-239 more into the subunit interface. ␤3Tyr-442 in ␤M4 is within 8 Å of ␤3Met-286 and ␤3Val- 
